Related Experiment Video
Updated: Apr 20, 2026
08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
10.2K
Serum ferroxidase activity in patients with multiple sclerosis: a pilot study.
Carlo Cervellati1, Arianna Romani2, Enrico Fainardi3
1Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, Italy crvcrl@unife.it.
In Vivo (Athens, Greece)
|November 16, 2014
Summary
Reduced serum ferroxidase (FeOx) activity, crucial for preventing oxidative stress, was observed in multiple sclerosis (MS) patients. This finding suggests a potential link between lower FeOx activity and inflammatory neurological disorders.
Area of Science:
- Neuroimmunology
- Oxidative Stress Research
- Biochemistry
Background:
- Oxidative stress is implicated in demyelination and axonal damage in multiple sclerosis (MS).
- Ceruloplasmin's ferroxidase (FeOx) activity is vital in preventing free radical formation by managing iron ions.
Purpose of the Study:
- To investigate serum FeOx activity in patients with MS compared to neurological controls.
- To explore the relationship between serum FeOx activity and disease activity markers in MS.
Main Methods:
- Serum FeOx activity was measured in 69 relapsing-remitting MS patients.
- Serum FeOx activity was also measured in 62 patients with other inflammatory neurological disorders (OIND) and 52 with non-inflammatory neurological disorders (NIND).
Main Results:
- Serum FeOx activity was significantly lower in MS and OIND groups compared to the NIND group (p<0.01).
- No significant differences in serum FeOx activity were found among MS patients categorized by clinical or MRI disease activity.
Conclusions:
- Reduced serum FeOx activity is a potential shared characteristic of inflammatory central nervous system disorders, including MS.
- Lower FeOx activity may contribute to increased oxidative stress and subsequent biomolecular damage in these conditions.
